ESSA Pharma (NASDAQ:EPIX – Get Free Report) (TSE:EPI) issued its earnings results on Monday. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.10, Zacks reports.
ESSA Pharma Trading Up 2.0 %
Shares of NASDAQ:EPIX traded up $0.09 on Wednesday, reaching $4.55. 21,321 shares of the company traded hands, compared to its average volume of 95,078. ESSA Pharma has a 52 week low of $2.58 and a 52 week high of $11.67. The business’s 50-day simple moving average is $5.26 and its 200 day simple moving average is $7.05. The stock has a market capitalization of $201.85 million, a P/E ratio of -7.60 and a beta of 1.82.
Wall Street Analyst Weigh In
Separately, Oppenheimer restated an “outperform” rating and issued a $17.00 price objective on shares of ESSA Pharma in a report on Thursday, May 16th.
ESSA Pharma Company Profile
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Further Reading
- Five stocks we like better than ESSA Pharma
- Comparing and Trading High PE Ratio Stocks
- What Are Bonds? A High-Level Overview
- When to Sell a Stock for Profit or Loss
- Super Micro Stock Drops Sharply After Earnings on Margin Concerns
- What Are Dividend Contenders? Investing in Dividend Contenders
- Lyft’s First-Ever Profit, but the Outlook Is a Speed Bump
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
